Fredun Pharmaceuticals Approves NSE Listing Application Alongside Strong Q2 Earnings
Fredun Pharmaceuticals Ltd · Others (Uncategorized) · 05 Nov 2026, 5:11 pm
Fredun Pharmaceuticals Approves NSE Listing Application Alongside Strong Q2 Earnings Fredun Pharmaceuticals' Board approved applying for listing on the NSE on 5th Nov'26. For Q2 ended 30th Sep'26, consolidated total income surged 84.19% YoY to ₹26,763.50 lakhs from ₹14,529.15 lakhs, while consolidated net profit jumped 96.93% YoY to ₹1,857.42 lakhs versus ₹943.17 lakhs in Q2 ended 30th Sep'25. Standalone net profit reached ₹1,882.57 lakhs with basic EPS of ₹11.21. For H1 ended 30th Sep'26, consolidated net profit rose 95.75% YoY to ₹3,170.65 lakhs. Statutory auditors issued unmodified limited review reports.
Original exchange filing (PDF)
More announcements from Fredun Pharmaceuticals Ltd
- Audio Recording Q2 & H1 FY27 Earnings Conference Call of Fredun Pharmaceuticals Limited. · 16 Nov 2026
- Outcome of the Board Meeting of 'Fredun Pharmaceuticals Limited' ('Company') pursuant to Regulation 30 of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. · 14 Nov 2026
- Report of Monitoring Agency on the use of proceeds raised through Preferential Allotment for the quarters ended March 31, 2026, June 30,2026 and September30, 2026. · 14 Nov 2026
- Statement of Deviation or Variation For the Quarter Ended September 30, 2026 for the Funds raised through Preferential Issue. · 14 Nov 2026
- Intimation of Earnings Conference Call for the Quarter Q2 of FY27 · 16 Nov 2026
- Press Release · 06 Nov 2026
- Financial results for the quarter ended 30th September, 2026. · 05 Nov 2026
- Outcome of the Board Meeting dated 05th November, 2026. · 05 Nov 2026
